Syros Pharmaceuticals (SYRS) Misses Q2 EPS by 17c, misses on revenue

Syros Pharmaceuticals (NASDAQ: SYRS) reported Q2 EPS of ($1.30), $0.17 worse than the analyst estimate of ($1.13). Revenue for the quarter came in at $2.8 million versus the consensus estimate of $3.5 million.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Morgan Stanley course-corrects their semiconductor equipment outlook on demand
• BMO starts chip stocks coverage: Here are its preferred picks